Hjem
Nyreforskningsgruppen

Varselmelding

There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there
Grants

Research grants summary

Grants as Principal Investigators: 2013-2023

Funding http://alphastockimages.com/
Foto/ill.:
Funding for research http://alphastockimages.com/

Hovedinnhold

Detailed Grants are found in the differents projects descriptions and their included links. This is a summary for the grants to the group in the last 10 years.

 

Public Funding

Grant ID

Granting body-Organization

Project

Amount (M.NOK)

Funding Period

Principal Investigator

 

Helse Vest (Strategic funding grant)

Digital Nephropathology Projects

20

2020 – 2024

Sabine Leh

341675

verifikasjonsmidler fra NFR

The Next Generation Kidney Function test

5

2023-2026

Olav Tenstad

HV912167

Helse Vest

Targeting Epithelial-to-Mesenchymal Transition to Treat Advanced Renal Cell Carcinoma: From Mice to Men!»

3.855

2017-2020

H.P. Marti

HV912233

Helse Vest

Targeting Renal Fibrosis: From Man to Zebrafish and Back to Man!

4.433

2018-2021

H.P. Marti

F-12559

Helse Vest (Strategic funding grant)

Digital technology for personalised management and therapy of hypertensive nephropathy

20

2020-2024

H.P. Marti

334097

Research Council of Norway

Single Cell Data-derived European Study for Personalised Management of Chronic Kidney Disease (CKD) in Children and Adolescents (Personalized management of MCD)

12

2023-2028

H.P. Marti

Industry Funds

Grant ID

Granting body-Organization

Project

Amount (M.NOK)

Funding Period

Principal Investigator

Alexion

Alexion Pharma Nordics AB NUF

Investigation of Complement System Activation in kidney diseases

0.3

2016-2019

H.P. Marti

Amicus

Amicus Therapeutics UK Limited

Effects of Migalastat in Fabry Nephropathy assessed by RNA sequencing of Kidney Biopsies

USD 66K

2017-2020

H.P. Marti

Genzyme

Sanofi Aventis (Genzyme) Norge

Fabry Nephropathy: Improved Therapy by Directed Drug Delivery

0.64

2014-2016

H.P. Marti

GZ-2013-11021

Sanofi-Genzyme

Improved Diagnosis and Therapy of Fabry Nephropathy by Biomarkers and by Novel Therapeutic Targets

Euro 280K

2014-2021

H.P. Marti

IIR NOR-00380

Takeda-Shire

Systems Medicine and Definition of Novel Drug Combination Therapy in Fabry Nephropathy

Euro 453.330

2015-2021

H.P. Marti

LS#37579

Alexion Pharmaceuticals

Investigation of Complement System Activation in Patients with IgA Nephropathy

Euro 99.750

2020-2024

H.P. Marti